Press Releases OptiNose, Inc.

Equities

OPTN

US68404V1008

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
1.03 ^USD	-9.65%		+25.46%	-20.16%

Apr. 25	OptiNose, Inc. Provides Revenue Guidance for the First Quarter of 2024	CI
Apr. 25	Transcript : OptiNose, Inc. - Special Call

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million	Apr. 25	AQ
Optinose to Present at the Needham Virtual Healthcare Conference	Apr. 04	AQ
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps	Mar. 15	AQ
Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?	Mar. 14	PR
OptiNose: Q4 Earnings Snapshot	Mar. 07	AQ
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights	Mar. 07	AQ
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results	Feb. 29	AQ
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice	Jan. 18	AQ
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE	Dec. 06	AQ
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference	Nov. 22	AQ
OptiNose: Q3 Earnings Snapshot	Nov. 09	AQ
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates	Nov. 09	AQ
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results	23-10-27	AQ
Optinose to Present at the 2023 Cantor Global Healthcare Conference	23-09-22	AQ
OptiNose: Q2 Earnings Snapshot	23-08-10	AQ
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates	23-08-10	AQ
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million	23-07-27	AQ
Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	23-06-16	AQ
OPTINOSE, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	23-06-13	AQ
Optinose to Present at the Jefferies Healthcare Conference	23-06-02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases OptiNose, Inc.

Equities

OPTN

US68404V1008

Press Releases

Filters